Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.60Alembic Pharmaceuticals Ltd. showcases a robust financial profile characterized by impressive growth, high profitability, and exceptional financial stability. The company's very low reliance on debt is a significant strength, providing a solid foundation and minimizing financial risk. This has enabled strong performance in both revenue and profit growth, indicating successful market strategies. Returns for shareholders are also strong. However, the company faces challenges in its operational efficiency. It takes a considerable amount of time to sell inventory and collect payments from customers, which can strain cash flow. While its ability to meet short-term obligations is generally adequate, its immediate cash reserves are low. The future outlook appears positive, driven by its financial strength and growth momentum, though operational effectiveness is a key area to monitor.
Health Score : 7.60Alembic Pharmaceuticals Ltd. showcases a robust financial profile characterized by impressive growth, high profitability, and exceptional financial stability. The company's very low reliance on debt is a significant strength, providing a solid foundation and minimizing financial risk. This has enabled strong performance in both revenue and profit growth, indicating successful market strategies. Returns for shareholders are also strong. However, the company faces challenges in its operational efficiency. It takes a considerable amount of time to sell inventory and collect payments from customers, which can strain cash flow. While its ability to meet short-term obligations is generally adequate, its immediate cash reserves are low. The future outlook appears positive, driven by its financial strength and growth momentum, though operational effectiveness is a key area to monitor.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
25.90
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
24.58
P/B RATIO
2.92
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
2.31
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
-2.42
EV/EBITDA RATIO
15.35
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹843.85 as on Sep 1, 2026.
Growth Score : 10.00The company is on an outstanding growth trajectory. It has demonstrated exceptional performance across all key growth indicators, including a strong rebound in sales and a significant increase in profitability. Earnings for shareholders have also expanded robustly. This comprehensive growth signals strong market demand for its products, effective business strategies, and successful execution. This upward trend is a major positive, indicating a healthy, expanding business that is likely increasing its market share and creating substantial value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -1.61 | 6.54 | 10.19 | 7.11 | 10.09 |
| Operating Profit Growth Rate | -40.95 | -21.97 | 36.66 | 8.15 | 10.91 |
| Earnings Per Share (EPS) Growth | -54.57 | -34.34 | 80.06 | -5.27 | 15.67 |
| Asset Growth Rate | 6.16 | -13.18 | 4.25 | 20.59 | 12.74 |
| Net Income Growth Rate | -54.54 | -34.36 | 80.12 | -5.52 | 15.29 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
No Peer Data Is Available at This Moment.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤4th Nov 25
Q2 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
Alembic Pharmaceuticals Ltd. is an integrated pharmaceutical company engaged in research, development, manufacturing, and marketing of pharmaceutical products. It offers branded generics in India, international generics, and active pharmaceutical ingredients (APIs) across diverse therapeutic areas, catering to both domestic and global markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Alembic Pharmaceuticals Ltd's P/E ratio (TTM) is 25.90, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Alembic Pharmaceuticals Ltd's P/B ratio is 2.92, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Alembic Pharmaceuticals Ltd's P/S ratio is 2.31, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Alembic Pharmaceuticals Ltd's PEG ratio is -2.42.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Alembic Pharmaceuticals Ltd's EV/EBITDA ratio is 15.35.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Alembic Pharmaceuticals Ltd's ROE is 11.82%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Alembic Pharmaceuticals Ltd's ROA is 12.76%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Alembic Pharmaceuticals Ltd's ROCE is 13%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Alembic Pharmaceuticals Ltd's operating margin is 15.22%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Alembic Pharmaceuticals Ltd's net margin is 9.14%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Alembic Pharmaceuticals Ltd's current ratio is 1.68.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Alembic Pharmaceuticals Ltd's debt-to-equity ratio is 0.03.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Alembic Pharmaceuticals Ltd's interest coverage ratio is 8.38.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Alembic Pharmaceuticals Ltd's DPS is ₹12.02.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Alembic Pharmaceuticals Ltd's EPS is 15.67.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹843.85. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1996
Headquarters: Vadodara, Gujarat
Core Offerings: Branded Generics (India), International Generics (US, EU, RoW), Active Pharmaceutical Ingredients (APIs), Research & Development
Stock Listing: NSE (APLLTD), BSE (533573)
Promoter: Amin Family / Alembic Group
Alembic Group's origins trace back to 1907 with Alembic Chemical Works Co. Ltd., pioneering pharmaceutical manufacturing in India. In 1996, its pharmaceutical business was demerged and incorporated as Alembic Pharmaceuticals Limited. The company significantly expanded its R&D capabilities and focused on international markets, particularly the US, from the early 2000s, leading to numerous ANDA approvals and establishing itself as a fully integrated global pharmaceutical company.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| India Formulations | 37% (FY23) | Operating Profit |
| International Formulations | 45% (FY23) | Operating Profit |
| Active Pharmaceutical Ingredients (APIs) | 18% (FY23) | Operating Profit |
India Formulations: Focuses on branded generics across therapeutic areas like gastrointestinal, dermatology, cardiology, and anti-infectives, leveraging a strong field force and distribution network.
International Formulations: Develops and markets generic products, primarily for the highly regulated US market, as well as Europe, Australia, and other emerging markets, with a robust pipeline of Abbreviated New Drug Applications (ANDAs).
Active Pharmaceutical Ingredients (APIs): Manufactures and sells APIs for both captive consumption and to third-party pharmaceutical companies globally, supporting both generic and innovator drug development.
Pranav Amin: Managing Director. He holds a degree in Pharmacy and has extensive experience within the pharmaceutical industry, crucial for the company's R&D and international growth. Shaunak Amin: Managing Director. With an MBA, he has been instrumental in the company's strategic planning and business development.
Alembic Global Holding SA
Alembic Pharmaceuticals Inc. (USA)
Alembic Pharma GmbH (Germany)
Alembic Pharmaceuticals (Pty) Ltd (South Africa)
Bonus Issue (1:2) in June 2015. No major recent corporate actions on record.
The Alembic Pharmaceuticals Ltd share price today is ₹843.85 on NSE (APLLTD), as of 26 Sept 2026.
As of 25 Sept 2026, Alembic Pharmaceuticals Ltd share price is ₹843.85, with previous close ₹843.85. Today's range is ₹843.85 to ₹843.85. The 52-week range is ₹635.80 to ₹920.
As of today, Alembic Pharmaceuticals Ltd's market cap is ₹17,003.58 crore (Mid Cap).
Alembic Pharmaceuticals Ltd's current P/E ratio is 25.90, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 27.
Alembic Pharmaceuticals Ltd's current P/B ratio is 2.92.
Alembic Pharmaceuticals Ltd's current dividend yield is 1.42%. Last dividend of ₹10.00 per share was declared on 24-May-2024.
Alembic Pharmaceuticals Ltd's EPS (TTM) is ₹15.67.
Alembic Pharmaceuticals Ltd. is an integrated pharmaceutical company engaged in research, development, manufacturing, and marketing of pharmaceutical products. It offers branded generics in India, international generics, and active pharmaceutical ingredients (APIs) across diverse therapeutic areas, catering to both domestic and global markets.
Alembic Pharmaceuticals Ltd is promoted by Amin Family / Alembic Group, holding 69.74% as of 25 Sept 2026.
Alembic Pharmaceuticals Ltd is listed on NSE (APLLTD) and BSE (533573). Its next quarterly results are expected on Q2 FY25 (October/November 2024).
Capital Expenditures (CapEx)
